Navidea Biopharmaceuticals Stock Price Prediction
| NAVB Stock | USD 0.0001 0.0004 80.00% |
Momentum 50
Impartial
Oversold | Overbought |
Using Navidea Biopharmaceutica hype-based prediction, you can estimate the value of Navidea Biopharmaceuticals from the perspective of Navidea Biopharmaceutica response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Navidea Biopharmaceutica to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying Navidea because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Navidea Biopharmaceutica after-hype prediction price | USD 8.5E-5 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as pink sheet price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Navidea |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Navidea Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Navidea Biopharmaceutica After-Hype Price Prediction Density Analysis
As far as predicting the price of Navidea Biopharmaceutica at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Navidea Biopharmaceutica or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Pink Sheet prices, such as prices of Navidea Biopharmaceutica, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Navidea Biopharmaceutica Estimiated After-Hype Price Volatility
In the context of predicting Navidea Biopharmaceutica's pink sheet value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Navidea Biopharmaceutica's historical news coverage. Navidea Biopharmaceutica's after-hype downside and upside margins for the prediction period are 0.00 and 50.01, respectively. We have considered Navidea Biopharmaceutica's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Navidea Biopharmaceutica is out of control at this time. Analysis and calculation of next after-hype price of Navidea Biopharmaceutica is based on 3 months time horizon.
Navidea Biopharmaceutica Pink Sheet Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Navidea Biopharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Navidea Biopharmaceutica backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Pink Sheet price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Navidea Biopharmaceutica, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
5.87 | 53.39 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.0001 | 0.000085 | 14.56 |
|
Navidea Biopharmaceutica Hype Timeline
Navidea Biopharmaceutica is now traded for 0.0001. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Navidea is anticipated to decline in value after the next headline, with the price expected to drop to 8.5E-5. The average volatility of media hype impact on the company price is insignificant. The price decrease on the next news is expected to be -14.56%, whereas the daily expected return is now at 5.87%. The volatility of related hype on Navidea Biopharmaceutica is about 0.0%, with the expected price after the next announcement by competition of 0.00. About 35.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.39. Navidea Biopharmaceutica last dividend was issued on the 26th of April 2019. The entity had 1:20 split on the 26th of April 2019. Given the investment horizon of 90 days the next anticipated press release will be uncertain. Check out Navidea Biopharmaceutica Basic Forecasting Models to cross-verify your projections.Navidea Biopharmaceutica Related Hype Analysis
Having access to credible news sources related to Navidea Biopharmaceutica's direct competition is more important than ever and may enhance your ability to predict Navidea Biopharmaceutica's future price movements. Getting to know how Navidea Biopharmaceutica's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Navidea Biopharmaceutica may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| GNBT | Generex Biotechnology Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| WPDPF | WPD Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NNMX | Nanomix | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NMDBF | NeonMind Biosciences | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| GLSHQ | Gelesis Holdings | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MOSTQ | MobileSmith | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| GDBYF | Goodbody Health | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CRXM | Taxus Cardium Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| MGFRF | MagForce AG | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ACORQ | Acorda Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Navidea Biopharmaceutica Additional Predictive Modules
Most predictive techniques to examine Navidea price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Navidea using various technical indicators. When you analyze Navidea charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Navidea Biopharmaceutica Predictive Indicators
The successful prediction of Navidea Biopharmaceutica stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Navidea Biopharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Navidea Biopharmaceutica based on analysis of Navidea Biopharmaceutica hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Navidea Biopharmaceutica's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Navidea Biopharmaceutica's related companies.
Story Coverage note for Navidea Biopharmaceutica
The number of cover stories for Navidea Biopharmaceutica depends on current market conditions and Navidea Biopharmaceutica's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Navidea Biopharmaceutica is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Navidea Biopharmaceutica's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Navidea Biopharmaceutica Short Properties
Navidea Biopharmaceutica's future price predictability will typically decrease when Navidea Biopharmaceutica's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Navidea Biopharmaceuticals often depends not only on the future outlook of the potential Navidea Biopharmaceutica's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Navidea Biopharmaceutica's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 29.3 M | |
| Cash And Short Term Investments | 2 M |
Complementary Tools for Navidea Pink Sheet analysis
When running Navidea Biopharmaceutica's price analysis, check to measure Navidea Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Navidea Biopharmaceutica is operating at the current time. Most of Navidea Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Navidea Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Navidea Biopharmaceutica's price. Additionally, you may evaluate how the addition of Navidea Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |